iShares Nasdaq Biotechnology Index Fund ETF News

Sector ETF report for IBB

Jefferies' Michael Yee joins 'Closing Bell' to discuss biotech stocks, which were one of the worst performers in today's sell-off. With CNBC's Michael Santoli.

The ALPS Medical Breakthroughs ETF (SBIO) was ALPS' top-performing ETF in August, propelled by positive earnings and M&A announcements in the portfolio.   SBIO increased 8.65% on a total return basi

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic

The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs

Biotechnology sector-related exchange traded funds are making a swift rebound as a spate of dealing making and new drug approvals helped reinvigorate the segment. For instance, the SPDR S&P Biotech ET

he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.

The Nasdaq Biotechnology ETF is a long-term outperformer but in the last years it lagged it peers. In the last weeks, this industry showed relative strength to the market and a comeback is probable.

Today's reaction to a high CPI print is the opposite of what we saw last month.

Smart Beta ETF report for IBB

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared

Older generations are showing their worry and providing a huge opportunity in the market's best retirement stocks for Gen-Z investors to buy The post The 3 Best Retirement Stocks for Gen-Z Investors a

Older generations are showing their worry and providing a huge opportunity in the market's best retirement stocks for Gen-Z investors to buy The post The 3 Best Retirement Stocks for Gen-Z Investors a

Jeff Degraaf, Renaissance Macro Research chairman, joins 'Closing Bell: Overtime' to discuss biotech and other sectors to watch.

Les Funtleyder, E Squared Capital Management healthcare portfolio manager, joins 'The Exchange' to discuss Biotech being slammed and if the sector can see a bounce.